EZH2 and gastric cancer: Additionally, lncRNA UCA1 can cause erlotinib resistance by activating the AKT/mTOR pathway and inducing EMT, and it can also promote gefitinib resistance by binding to EZH2 and silencing CDKN1A epigenetically.701 Studies have demonstrated that LINC00665 can modulate SERPINE1 and enhance p-AKt expression within the PI3K/AKt pathway, resulting in trastuzumab resistance in gastric cancer.702 Additionally, lncRNAs could boost receptor signaling, which in turn heightens resistance to targeted therapies.